Matthew Frigault, MD, MS, on CART-ddBCMA's Potential in Multiple Myeloma
The study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape.
CART-ddBCMA, an investigational autologous chimeric antigen receptor (CAR) T-cell therapy which uses a novel synthetic binding domain referred to as a D-Domain to target B-cell maturation antigen (BCMA), has continued to demonstrate clinical activity and a manageable safety profile in a phase 1 study (NCT04155749) in patients with relapsed/refractory (r/r) multiple myeloma (MM), according to updated data presented at the 64th Annual American Society of Hematology (ASH) Meeting, held December 10-13, 2022, in New Orleans, Louisiana.
CGTLive sat down with primary investigator Matthew Frigault, MD, MS, of Mass General, to learn more about the latest results and where the novel therapy may fit into the treatment landscape.
For more coverage of ASH 2022, click here.
REFERENCE
Frigault M, Rosenblatt JR, Dhakal, B, et al. Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma. Presented at: 2022 ASH Annual Meeting. December 10-13, 2022; New Orleans, LA. Abstract 33132.
Considerations for Administering Hemoglobinopathy Gene Therapies From a Pharmacist’s Perspective
April 20th 2024Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at Mayo Clinic, discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.
